International journal of cardiology · 2018
Impact of end stage renal disease on in-hospital outcomes of patients with systolic and diastolic heart failure (insights from the Nationwide Inpatient Sample 2010 to 2014).
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Lemor Alejandro, Hernandez Gabriel A, Lee Shawn, Patel Nish, Blumer Vanessa, Badiye Amit, Alfonso Carlos, Fonarow Gregg C, Lindenfeld JoAnn, Chaparro Sandra
Аннотация
BACKGROUND: Heart Failure (HF) and end stage renal disease (ESRD) are associated with increased morbidity, mortality, and are responsible for an immense economic burden. We sought to evaluate the impact of ESRD in heart failure by using a national cohort.
METHODS: This is a retrospective cohort study using the National Inpatient Sample (NIS) of patients hospitalized with HF from 2010 to 2014. The primary outcome was in-hospital mortality. Multivariate regression was used for the statistical analysis.
RESULTS: We identified a total 1,587,172 patients with systolic HF and 1,316,220 with diastolic HF. Patients with systolic HF and ESRD had higher in-hospital mortality (4.6% vs 2.7% OR: 1.86, p < 0.001). The in-hospital mortality in diastolic HF and ESRD was 2.7% vs 2.5% in those without ESRD (OR:1.11, p = 0.03). Patients with systolic HF and ESRD had significantly higher rates of ICU admissions (OR: 1.56, p < 0.001), mean length of stay (+1.5 days, p < 0.001), median hospital costs (p < 0.001), and acute respiratory failure (OR: 1.58, p < 0.001). Similarly, patients with diastolic HF and ESRD also had significantly higher rates of ICU admissions (OR: 1.59, p < 0.001), acute respiratory failure (OR: 1.54, p < 0.001), mean length of stay (+1.1 days, p < 0.001), and median hospital costs (p < 0.001).
CONCLUSION: ESRD is associated with significantly increased in-hospital mortality in HF but the increase is nearly two-fold (86%) for systolic HF and very modest (11%) in diastolic HF. However, hospital costs, ICU admissions, acute respiratory failure, and length of stay are similarly higher for patients with both systolic and diastolic HF and ESRD.
METHODS: This is a retrospective cohort study using the National Inpatient Sample (NIS) of patients hospitalized with HF from 2010 to 2014. The primary outcome was in-hospital mortality. Multivariate regression was used for the statistical analysis.
RESULTS: We identified a total 1,587,172 patients with systolic HF and 1,316,220 with diastolic HF. Patients with systolic HF and ESRD had higher in-hospital mortality (4.6% vs 2.7% OR: 1.86, p < 0.001). The in-hospital mortality in diastolic HF and ESRD was 2.7% vs 2.5% in those without ESRD (OR:1.11, p = 0.03). Patients with systolic HF and ESRD had significantly higher rates of ICU admissions (OR: 1.56, p < 0.001), mean length of stay (+1.5 days, p < 0.001), median hospital costs (p < 0.001), and acute respiratory failure (OR: 1.58, p < 0.001). Similarly, patients with diastolic HF and ESRD also had significantly higher rates of ICU admissions (OR: 1.59, p < 0.001), acute respiratory failure (OR: 1.54, p < 0.001), mean length of stay (+1.1 days, p < 0.001), and median hospital costs (p < 0.001).
CONCLUSION: ESRD is associated with significantly increased in-hospital mortality in HF but the increase is nearly two-fold (86%) for systolic HF and very modest (11%) in diastolic HF. However, hospital costs, ICU admissions, acute respiratory failure, and length of stay are similarly higher for patients with both systolic and diastolic HF and ESRD.